Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
Sponsor: EMD Serono Research & Development Institute, Inc.
Listed as NCT04448756, this PHASE2 trial focuses on Coronavirus Disease 2019 and remains completed. Sponsored by EMD Serono Research & Development Institute, Inc., it has been updated 16 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EMD Serono Research & Development Institute, Inc.
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .